The Oligonucleotide Therapeutics Society Celebrates Another Remarkable Annual Meeting
09 oct. 2021 12h00 HE
|
The Oligonucleotide Therapeutics Society
SAN DIEGO, Oct. 09, 2021 (GLOBE NEWSWIRE) -- The Oligonucleotide Therapeutics Society's 17th Annual Meeting was held virtually the second year in a row and was once again phenomenally successful....
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
29 sept. 2021 07h00 HE
|
Fortress Biotech, Inc.
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and...
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
15 déc. 2020 19h17 HE
|
Novartis International AG
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval...
Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event
02 déc. 2020 11h36 HE
|
Axiom Real-Time Metrics Inc
TORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at Clinical Trials...
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
19 nov. 2020 08h00 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the...
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
20 oct. 2020 08h00 HE
|
Asklepios BioPharmaceutical, Inc.
WATERTOWN, Mass., and Research Triangle Park, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the...
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
01 oct. 2020 01h15 HE
|
Novartis International AG
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6...
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
29 août 2020 06h30 HE
|
Novartis International AG
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on...
AskBio Appoints Michael Kranda as SVP Therapeutic Practice Leader for Its Growing CNS Portfolio
06 août 2020 08h00 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
Allsup Joins NORD To Address COVID-19 Concerns
29 juil. 2020 13h34 HE
|
Allsup
Belleville, Illinois, July 29, 2020 (GLOBE NEWSWIRE) -- Patients and families affected by rare diseases are gravely concerned about COVID-19 and its impact on their health and financial well-being,...